Search results
Here’s what a Nobel Prize-winning scientist wants you to know about the Covid-19 vaccines and the...
CNN via Yahoo News· 13 hours agoIn his new book “The Catalyst,” Thomas R. Cech talks about the Covid-19 vaccines, what RNA means for...
US scientists create world’s first seedless blackberry using CRISPR
Interesting Engineering· 15 hours agoThis has led them to develop the world’s first seedless blackberry. Short for Clustered Regularly...
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Motley Fool via Yahoo Finance· 2 days agoCathie Wood is buying the dip on two biotechs in particular, so for her, the answer to that question...
In Central Florida, scientists battle citrus disease with genetic engineering
WUSF 89.7· 16 hours agoOne March morning, more than eighty years after his family first started growing oranges in DeLeon...
Cathie Wood's ARK buys PagerDuty, CRISPR, sells Zoom stock By Investing.com
Investing.com· 5 days agoCathie Wood's ARK buys PagerDuty, CRISPR, sells Zoom stock
Small Business - Picayune Item | Picayune Item
The Picayune Item· 6 days agoBERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today ...
A Single Mutation Gave These Fish a Sense of Curiosity And Opened Up Their World
ScienceAlert via Yahoo News· 5 hours agoSpecies bearing a "T" (for thymine) at this site in their DNA exhibit more curiosity, the...
‘The Catalyst’ Review: The RNA Renaissance
The Wall Street Journal· 8 hours agoThe unassuming bacteria E. coli, similarly, led to the discovery of the Crispr system that has since been used to develop techniques for gene editing and...
Evercore ISI cuts Editas Medicine stock target By Investing.com
Investing.com· 6 days agoThe firm's analyst has reduced the price target for the company's shares to $7.00 from the previous...
Intellia’s CRISPR drug shows promise against hereditary angioedema in early-stage trial - Boston...
The Business Journals· 4 days agoOn Sunday, Intellia Therapeutics (Nasdaq: NTLA) said that its experimental gene-editing treatment...